Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease.

Coma M, Serenó L, Da Rocha-Souto B, Scotton TC, España J, Sánchez MB, Rodríguez M, Agulló J, Guardia-Laguarta C, Garcia-Alloza M, Borrelli LA, Clarimón J, Lleó A, Bacskai BJ, Saura CA, Hyman BT, Gómez-Isla T.

Neurobiol Dis. 2010 Jun;38(3):482-91. doi: 10.1016/j.nbd.2010.01.019.

2.

Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.

Dobarro M, Gerenu G, Ramírez MJ.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2245-57. doi: 10.1017/S1461145713000631.

PMID:
23768694
3.

Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.

Shin MK, Kim HG, Baek SH, Jung WR, Park DI, Park JS, Jo DG, Kim KL.

Neurobiol Aging. 2014 May;35(5):990-1001. doi: 10.1016/j.neurobiolaging.2013.10.091.

PMID:
24268884
4.

Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.

O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X.

Brain Pathol. 2008 Oct;18(4):548-61. doi: 10.1111/j.1750-3639.2008.00152.x.

5.

Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.

Ribeiro CA, Oliveira SM, Guido LF, Magalhães A, Valencia G, Arsequell G, Saraiva MJ, Cardoso I.

J Alzheimers Dis. 2014;39(2):357-70. doi: 10.3233/JAD-131355.

PMID:
24169237
6.

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.

Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calzà L, Flaibani R, Spano PF, Imbimbo BP, Pizzi M.

Neuroscience. 2015 Aug 27;302:112-20. doi: 10.1016/j.neuroscience.2014.10.029.

PMID:
25450955
7.

Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.

Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K.

Neurobiol Dis. 2014 Nov;71:110-30. doi: 10.1016/j.nbd.2014.07.001.

PMID:
25046994
8.

IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.

Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA.

J Immunol. 2013 Mar 1;190(5):2241-51. doi: 10.4049/jimmunol.1200947.

9.

TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K.

J Neuroinflammation. 2011 Aug 9;8:92. doi: 10.1186/1742-2094-8-92.

10.

Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates Aβ pathology and improves cognitive function.

Kim TK, Han HE, Kim H, Lee JE, Choi D, Park WJ, Han PL.

Exp Mol Med. 2012 Dec 31;44(12):740-8. doi: 10.3858/emm.2012.44.12.082.

11.

Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Dong H, Murphy KM, Meng L, Montalvo-Ortiz J, Zeng Z, Kolber BJ, Zhang S, Muglia LJ, Csernansky JG.

J Alzheimers Dis. 2012;28(3):579-92. doi: 10.3233/JAD-2011-111328.

12.

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M.

J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.

13.

Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model.

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu XG, Chui D, Liu G.

Mol Brain. 2014 Sep 13;7:65. doi: 10.1186/s13041-014-0065-y.

14.

Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.

Wang T, Wang CY, Shan ZY, Teng WP, Wang ZY.

J Alzheimers Dis. 2012;29(3):549-59. doi: 10.3233/JAD-2011-111874.

PMID:
22269164
15.

Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model.

Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W.

Curr Alzheimer Res. 2010 May;7(3):255-61.

PMID:
20043809
16.

Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease.

Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, Cheng D, Karl T, Garner B.

J Neurosci. 2013 Mar 6;33(10):4387-94. doi: 10.1523/JNEUROSCI.4165-12.2013.

17.

Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z.

Am J Pathol. 2009 Nov;175(5):2099-110. doi: 10.2353/ajpath.2009.090159. Erratum in: Am J Pathol. 2010 Apr;176(4):2055.

18.

Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology.

Münch G, Apelt J, Rosemarie-Kientsch-Engel, Stahl P, Lüth HJ, Schliebs R.

J Neurochem. 2003 Jul;86(2):283-9.

19.

Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice.

Lull ME, Levesque S, Surace MJ, Block ML.

PLoS One. 2011;6(5):e20153. doi: 10.1371/journal.pone.0020153.

20.
Items per page

Supplemental Content

Support Center